Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Research Council grant · Running

NEUROSHIELD Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease

Coordinator
Universidade Nova De Lisboa, Portugal
Runs
1 June 2025 to 30 November 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101188579

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on administration of dopamine precursors or analogues. Neuroinflammation is a central hallmark of PD, however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness driving to neuronal death.

NEUROSHIELD will address this gap in PD treatment, to ensure an increased quality of life of PD patients, while exploiting this therapeutic market opportunity. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or raised long-term usage complications due to adverse side-effects. NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, different mechanism to the classic NSAID COX-2 inhibitors mechanism.

We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation. NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway

Who is involved

OrganisationCityCountryRole
Universidade Nova De LisboaLisboaPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI